跳至主要内容
临床试验/NCT01076634
NCT01076634已完成1 期

A Trial Investigating the Pharmacodynamic Properties of NN1250 in Subjects With Type 1 Diabetes

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2010年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
33
试验地点
1
主要终点
Area under the glucose infusion rate curve during one dosing interval at steady-date"

研究概览

简要总结

This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 (insulin degludec, IDeg) formulations in subjects with type 1 diabetes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months
  • Body mass index 18.0-28.0 kg/m^2 (both inclusive)

排除标准

  • Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
  • Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
  • Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period

研究组 & 干预措施

IDeg 100 U/mL

Experimental

干预措施: insulin degludec (Drug)

IDeg 200 U/mL

Experimental

干预措施: insulin degludec (Drug)

结局指标

主要结局

Area under the glucose infusion rate curve during one dosing interval at steady-date"

时间窗: After 8 days of treatment

次要结局

  • Area under the serum Insulin Degludec concentration-time curve(From 0 to 24 hours after single dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验